Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBIT (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBIT for 13 consecutive years, with -$6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 40.44% to -$6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$32.8 million, a 29.45% increase, with the full-year FY2024 number at -$9.2 million, up 80.39% from a year prior.
  • EBIT was -$6.5 million for Q3 2025 at Theravance Biopharma, down from -$2.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$2.7 million in Q2 2025 to a low of -$83.9 million in Q1 2021.
  • A 5-year average of -$24.3 million and a median of -$15.7 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: surged 82.95% in 2022, then dropped 28.79% in 2025.
  • Theravance Biopharma's EBIT stood at -$53.6 million in 2021, then soared by 67.49% to -$17.4 million in 2022, then skyrocketed by 49.75% to -$8.8 million in 2023, then dropped by 5.02% to -$9.2 million in 2024, then increased by 29.85% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBIT are -$6.5 million (Q3 2025), -$2.7 million (Q2 2025), and -$14.4 million (Q1 2025).